Monoclonal antibodies (mAbs), which are targeted against many cancer-associated markers (e.g., CD20, EGFR, HER-2, CD38) or checkpoint molecules, represent a large and rapidly growing class of cancer (immuno)therapies today, constituting of over 50% of more than 100 antibodies currently available for routine clinical use [1]. This evidence concerns the gene ERBB2 and cancer.